Neumora Therapeutics Cash Flow Statement 2022-2024 | NMRA

Fifteen years of historical annual cash flow statements for Neumora Therapeutics (NMRA).

Annual Data | Millions of US $ except per share data

Metric Name
Net Income/Loss
Total Depreciation And Amortization - Cash Flow
Other Non-Cash Items
Total Non-Cash Items
Change In Accounts Receivable
Change In Inventories
Change In Accounts Payable
Change In Assets/Liabilities
Total Change In Assets/Liabilities
Cash Flow From Operating Activities
Net Change In Property, Plant, And Equipment
Net Change In Intangible Assets
Net Acquisitions/Divestitures
Net Change In Short-term Investments
Net Change In Long-Term Investments
Net Change In Investments - Total
Investing Activities - Other
Cash Flow From Investing Activities
Net Long-Term Debt
Net Current Debt
Debt Issuance/Retirement Net - Total
Net Common Equity Issued/Repurchased
Net Total Equity Issued/Repurchased
Total Common And Preferred Stock Dividends Paid
Financial Activities - Other
Cash Flow From Financial Activities
Net Cash Flow
Stock-Based Compensation
Common Stock Dividends Paid
20232022
$-235.93$-130.90
$-3.07$-0.11
$84.62$23.07
$81.55$22.96
$0$0
$0$0
$-0.58$-1.25
$-8.32$-5.70
$-8.90$-6.95
$-163.28$-114.90
$-0.12$-0.51
$0$0
$0$0
$0$0
$69.09$-154.50
$69.09$-154.50
$-4.59$-13.00
$64.39$-168.01
$0$0
$0$0
$0$0
$236$4.27
$236$116
$0$0
$-3.80$-0.74
$232$116
$133$-167.17
$17.24$8.30
$0$0